Greg Yothers

Also affiliated with NRG Oncology

MedicineMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 43 papers. Top paper: “Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database”.

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database

Annals of Oncology(2020)10.1016/j.annonc.2019.12.007

N/A

1.4DataRank · unranked

34 citations

Jun Yin, Richard M. Goldberg, Levi Pederson, Norman Wolmark, Steven R. Alberts +11 more

Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer

BMC Cancer(2024)10.1186/s12885-024-12529-7

N/A

0.808DataRank · unranked

39 citations

Qian Shi, Arvind Dasari, Julio García‐Aguilar, Hanna Sanoff, Thomas J. George +25 more

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04

Cancer(2022)10.1002/cncr.34341

N/A

0.682DataRank · unranked

11 citations

Ron D. Hays, Karen L. Spritzer, André Rogatko, Clifford Y. Ko, Linda H. Colangelo +5 more

Utilizing Patient Input in Rectal Cancer Trial Design

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf074

N/A

0.241DataRank · unranked

4 citations

Wini Zambare, Manju George, Reese Garcia, Phuong Gallagher, Caleah Kitchens +22 more

Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04

Quality of Life Research(2024)10.1007/s11136-024-03746-5

N/A

0.225DataRank · unranked

3 citations

Jessica Roydhouse, Mourad Tighiouart, N. Lynn Henry, Sungjin Kim, Ron D. Hays +4 more

Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance)

Cancer Epidemiology Biomarkers & Prevention(2020)10.1158/1055-9965.epi-20-1274

N/A

0.216DataRank · unranked

2 citations

Xinwei Hua, Tabitha A. Harrison, Barbara L. Banbury, Jeroen R. Huyghe, Wei Sun +13 more

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial

JNCI Cancer Spectrum(2025)10.1093/jncics/pkaf032

N/A

0.208DataRank · unranked

3 citations

Sungjin Kim, N. Lynn Henry, Ron D. Hays, Vinícius F. Calsavara, Michael Luu +11 more

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3618

N/A

0DataRank · unranked

7 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps148

N/A

0DataRank · unranked

5 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps158

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3622

N/A

0DataRank · unranked

2 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae

BMC Medical Research Methodology(2021)10.1186/s12874-021-01368-w

N/A

0DataRank · unranked

0 citations

Gillian Gresham, Sungjin Kim, Michael Luu, N. Lynn Henry, Mourad Tighiouart +4 more

Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3516

N/A

0DataRank · unranked

0 citations

Marion Joy, Ying Wang, Nan Song, Rim S. Kim, Greg Yothers +12 more

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.09.159

N/A

0DataRank · unranked

450 citations

Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross +93 more

Racial disparity in distant recurrence‐free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials

Cancer(2022)10.1002/cncr.34241

N/A

0DataRank · unranked

25 citations

Jessica Pastoriza, Jiyue Qin, Juan Lin, George S. Karagiannis, John S. Condeelis +9 more

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30

npj Breast Cancer(2022)10.1038/s41523-022-00489-9

N/A

0DataRank · unranked

9 citations

Sungjin Kim, Ron D. Hays, Márcio A. Diniz, Mourad Tighiouart, Gillian Gresham +6 more

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps212

N/A

0DataRank · unranked

7 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +8 more

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps232

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3647

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps233

N/A

0DataRank · unranked

3 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3643

N/A

0DataRank · unranked

3 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +9 more

Five- or 10-year colonoscopy for 1-2 non-advanced adenomatous polyps (FORTE) NRG-CC005 study: A randomized phase III non-inferiority trial comparing colorectal cancer incidence in participants with 1-2 non-advanced adenomas randomized to a 5- and 10-year surveillance colonoscopy exam schedule versus a 10-year surveillance colonoscopy exam schedule.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3631

N/A

0DataRank · unranked

1 citations

Hanna Bandos, Douglas Corley, Jeff Dueker, Greg Yothers, Jinbing Bai +6 more

Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3607

N/A

0DataRank · unranked

1 citations

Lujia Chen, Ying Wang, Chunhui Cai, Rim S. Kim, Corey Lipchik +12 more

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.140

N/A

0DataRank · unranked

0 citations

Marion Joy, Ying Wang, Rim S. Kim, Patrick G. Gavin, Debora Fumagalli +13 more

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

The Lancet(2023)10.1016/s0140-6736(23)00285-4

N/A

0DataRank · unranked

195 citations

Rosie Bradley, Richard Gray, Robert K. Hills, Hongchao Pan, Richárd Pető +95 more

Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial

Cancer Prevention Research(2023)10.1158/1940-6207.capr-23-0216

N/A

0DataRank · unranked

4 citations

N. Lynn Henry, Ron D. Hays, Sungjin Kim, Michael Luu, Márcio A. Diniz +7 more

NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad143

N/A

0DataRank · unranked

2 citations

Rebecca C. Auer, May Cho, N.A. Dasari, Cynthia Davies-Venn, Cathy Eng +36 more

Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.7

N/A

0DataRank · unranked

40 citations

Greg Yothers, Osama E. Rahma, Theodore S. Hong, Marcia M. Russell, Y. Nancy You +14 more

Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3640

N/A

0DataRank · unranked

21 citations

Arvind Dasari, Qian Shi, Julio García‐Aguilar, Hanna K. Sanoff, Thomas J. George +13 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps258

N/A

0DataRank · unranked

1 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps259

N/A

0DataRank · unranked

1 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3634

N/A

0DataRank · unranked

1 citations

Yu Guan, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Sahin +10 more

NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps260

N/A

0DataRank · unranked

0 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +10 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3625

N/A

0DataRank · unranked

0 citations

Greg Yothers, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Atif Iqbal +8 more

Analyses of adverse events and patient‐reported outcomes with the toxicity index in cancer clinical trials

Cancer(2025)10.1002/cncr.70086

N/A

0DataRank · unranked

1 citations

N. Lynn Henry, Hanna Bandos, Vinícius F. Calsavara, Reena S. Cecchini, Márcio A. Diniz +8 more

Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa028

N/A

0DataRank · unranked

40 citations

Márcio A. Diniz, Zahra S. Razaee, Michael Luu, Sungjin Kim, Ron D. Hays +6 more

Trials in progress: Alliance A022104/NRG-GI010—A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC; the Janus Rectal Cancer trial).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.tps3650

N/A

0DataRank · unranked

0 citations

Qian Shi, Arvind Dasari, Julio García‐Aguilar, Hanna K. Sanoff, Thomas J. George +15 more

NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps261

N/A

0DataRank · unranked

17 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps260

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps4121

N/A

0DataRank · unranked

4 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4099

N/A

0DataRank · unranked

1 citations

Jesse G. Dixon, Hiral D. Parekh, Steven R. Alberts, Greg Yothers, Carmen J. Allegra +15 more

Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab187

N/A

0DataRank · unranked

16 citations

Mohamed E. Salem, Jesse G. Dixon, Zhaohui Jin, Romain Cohen, Aimery DeGramont +16 more

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.8

N/A

0DataRank · unranked

32 citations

Greg Yothers, Theodore S. Hong, Marcia M. Russell, Y. Nancy You, William Parker +10 more